Key result
Nucleoside analogs hold great potential as inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase, with recent structural and computational research elucidating their underlying molecular mechanisms.
Why the study?
SARS-CoV-2 RNA-dependent RNA polymerase is a key antiviral target, making a summary of experimental findings and molecular inhibitory mechanisms of nucleoside analogs needed to guide rational drug design.
Design
Review
Authors
Loading...
Experimental data support nucleoside analogs as RdRp inhibitors; leaves open clinical translation for COVID-19.
This review summarizes the molecular mechanisms of nucleoside analogs inhibiting SARS-CoV-2 RdRp to guide rational design of antiviral medications.
Xu et al. (2023) conducted a review in COVID-19 (SARS-CoV-2). Nucleoside analogs was evaluated. Nucleoside analogs hold great potential as inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase, with recent structural and computational research elucidating their underlying molecular mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: